Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-02-05 6:28 pm Purchase |
2024-12-31 | 13G | Gossamer Bio, Inc. GOSS |
Octagon Capital Advisors LP | 19,576,054 8.600% |
19,576,054 (New Position) |
Filing History |
| 2025-02-05 6:05 pm Purchase |
2024-12-31 | 13G | Taysha Gene Therapies, Inc. TSHA |
Octagon Capital Advisors LP | 10,450,000 5.100% |
10,450,000 (New Position) |
Filing History |
| 2025-02-05 5:42 pm Purchase |
2024-12-31 | 13G | Dianthus Therapeutics, Inc. DNTH |
Octagon Capital Advisors LP | 2,110,167 7.100% |
363,500 (+20.81%) |
Filing History |
| 2024-10-28 4:03 pm Purchase |
2024-10-04 | 13G | OnKure Therapeutics, Inc. OKUR |
Octagon Capital Advisors LP | 225,000 1.800% |
225,000 (New Position) |
Filing History |
| 2024-10-11 4:02 pm Purchase |
2024-09-30 | 13G | AlloVir, Inc. ALVR |
Octagon Capital Advisors LP | 487,043 9.700% |
487,043 (New Position) |
Filing History |
| 2024-10-11 4:02 pm Purchase |
2024-09-30 | 13G | ArriVent BioPharma, Inc. Common Stock AVBP |
Octagon Capital Advisors LP | 1,976,387 5.900% |
1,976,387 (New Position) |
Filing History |
| 2024-10-11 4:02 pm Purchase |
2024-09-30 | 13G | Corbus Pharmaceuticals Holdings, Inc. CRBP |
Octagon Capital Advisors LP | 1,115,000 9.300% |
1,115,000 (New Position) |
Filing History |
| 2024-10-11 4:02 pm Purchase |
2024-09-30 | 13G | Dianthus Therapeutics, Inc. DNTH |
Octagon Capital Advisors LP | 1,746,667 6.000% |
1,746,667 (New Position) |
Filing History |
| 2024-10-11 4:02 pm Purchase |
2024-09-30 | 13G | Regulus Therapeutics Inc. RGLS |
Octagon Capital Advisors LP | 4,263,701 6.500% |
4,263,701 (New Position) |
Filing History |
| 2024-10-11 4:02 pm Purchase |
2024-09-30 | 13G | Unicycive Therapeutics, Inc. UNCY |
Octagon Capital Advisors LP | 8,559,000 9.100% |
8,559,000 (New Position) |
Filing History |
| 2024-08-28 4:02 pm Sale |
2024-08-26 | 13G | AN2 Therapeutics, Inc. ANTX |
Octagon Capital Advisors LP | 0 0.000% |
-3,009,927 (Position Closed) |
Filing History |
| 2024-07-03 08:02 am Purchase |
2024-06-13 | 13G | AN2 Therapeutics, Inc. ANTX |
Octagon Capital Advisors LP | 3,009,927 10.100% |
3,009,927 (New Position) |
Filing History |
| 2024-02-06 4:04 pm Sale |
2024-01-02 | 13G | Xilio Therapeutics, Inc. XLO |
Octagon Capital Advisors LP | 0 0.000% |
-1,785,000 (Position Closed) |
Filing History |
| 2024-02-05 4:01 pm Purchase |
2023-12-31 | 13G | Reneo Pharmaceuticals, Inc. RPHM |
Octagon Capital Advisors LP | 225,000 6.750% |
225,000 (New Position) |
Filing History |
| 2024-02-05 4:01 pm Sale |
2023-12-31 | 13G | Xilio Therapeutics, Inc. XLO |
Octagon Capital Advisors LP | 1,785,000 6.480% |
-640,000 (-26.39%) |
Filing History |
| 2023-01-25 4:01 pm Purchase |
2022-12-31 | 13G | Xilio Therapeutics, Inc. XLO |
Octagon Capital Advisors LP | 2,425,000 8.830% |
2,425,000 (New Position) |
Filing History |